These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 29596544)

  • 1. Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non-Small Cell Lung Cancer.
    Hong S; Gao F; Fu S; Wang Y; Fang W; Huang Y; Zhang L
    JAMA Oncol; 2018 May; 4(5):739-742. PubMed ID: 29596544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-invasive detection of actionable mutations in advanced non-small-cell lung cancer using targeted sequencing of circulating tumor DNA.
    Sim WC; Loh CH; Toh GL; Lim CW; Chopra A; Chang AYC; Goh LL
    Lung Cancer; 2018 Oct; 124():154-159. PubMed ID: 30268455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The concomitant gene alterations impact the therapeutic efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with epidermal growth factor receptor sensitive mutation].
    Li JM; Hu J; Bai CX; Zhang Y; Xu XB; Wang XD; Ding N
    Zhonghua Jie He He Hu Xi Za Zhi; 2018 Oct; 41(10):778-782. PubMed ID: 30347549
    [No Abstract]   [Full Text] [Related]  

  • 5. Circulating plasma microRNAs as potential markers to identify EGFR mutation status and to monitor epidermal growth factor receptor-tyrosine kinase inhibitor treatment in patients with advanced non-small cell lung cancer.
    Qu L; Li L; Zheng X; Fu H; Tang C; Qin H; Li X; Wang H; Li J; Wang W; Yang S; Wang L; Zhao G; Lv P; Lei Y; Zhang M; Gao H; Song S; Liu X
    Oncotarget; 2017 Jul; 8(28):45807-45824. PubMed ID: 28496005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of advanced EGFR-mutant NSCLC patients: Sequencing matters.
    Estevinho F; Felizardo M; Fernandes G; Figueiredo A; Lopes JA
    Pulmonology; 2019; 25(5):306-309. PubMed ID: 31182368
    [No Abstract]   [Full Text] [Related]  

  • 7. Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy.
    Liao BC; Lin CC; Lee JH; Yang JC
    Lung Cancer; 2017 Aug; 110():7-13. PubMed ID: 28676222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (
    Han JY; Lee KH; Kim SW; Min YJ; Cho E; Lee Y; Lee SH; Kim HY; Lee GK; Nam BH; Han H; Jung J; Lee JS
    Cancer Res Treat; 2017 Jan; 49(1):10-19. PubMed ID: 27188206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations.
    Ichihara E; Hotta K; Takigawa N; Kudo K; Kato Y; Honda Y; Hayakawa H; Minami D; Sato A; Tabata M; Tanimoto M; Kiura K
    Lung Cancer; 2013 Sep; 81(3):435-439. PubMed ID: 23809059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.
    Lou NN; Zhang XC; Chen HJ; Zhou Q; Yan LX; Xie Z; Su J; Chen ZH; Tu HY; Yan HH; Wang Z; Xu CR; Jiang BY; Wang BC; Bai XY; Zhong WZ; Wu YL; Yang JJ
    Oncotarget; 2016 Oct; 7(40):65185-65195. PubMed ID: 27533086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant TKIs - a long-term matter.
    Romero D
    Nat Rev Clin Oncol; 2019 Feb; 16(2):67. PubMed ID: 30487531
    [No Abstract]   [Full Text] [Related]  

  • 12. Third generation EGFR TKI landscape for metastatic EGFR mutant non-small cell lung cancer (NSCLC).
    Tan AC; Teh YL; Lai GGY; Tan DSW
    Expert Rev Anticancer Ther; 2019 Jun; 19(6):431-435. PubMed ID: 30950666
    [No Abstract]   [Full Text] [Related]  

  • 13. Third-generation EGFR-TKIs—a new hope for NSCLC.
    Akkermans R
    Lancet Respir Med; 2014 Jul; 2(7):520. PubMed ID: 25140365
    [No Abstract]   [Full Text] [Related]  

  • 14. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
    Chung C
    J Oncol Pharm Pract; 2016 Jun; 22(3):461-76. PubMed ID: 25855240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer.
    Pao W; Chmielecki J
    Nat Rev Cancer; 2010 Nov; 10(11):760-74. PubMed ID: 20966921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma.
    Cadranel J; Ruppert AM; Beau-Faller M; Wislez M
    Crit Rev Oncol Hematol; 2013 Dec; 88(3):477-93. PubMed ID: 23911281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Afatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with Rare EGFR (in exon 18-T179X) Mutation - a Case Report.
    Čoupková H; Vyzula R
    Klin Onkol; 2018; 31(5):380-383. PubMed ID: 30541326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Afatinib in Osimertinib-Resistant EGFR ex19del/T790M/P794L Mutated NSCLC.
    van Kempen LC; Wang H; Aguirre ML; Spatz A; Kasymjanova G; Vilacha JF; Groves MR; Agulnik J; Small D
    J Thorac Oncol; 2018 Sep; 13(9):e161-e163. PubMed ID: 29704676
    [No Abstract]   [Full Text] [Related]  

  • 19. An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.
    Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Expert Rev Mol Diagn; 2017 Oct; 17(10):933-942. PubMed ID: 28838271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP).
    Hirsch FR; Sequist LV; Gore I; Mooradian M; Simon G; Croft EF; DeVincenzo D; Munley J; Stein D; Freivogel K; Sifakis F; Bunn PA
    Cancer; 2018 Jun; 124(11):2407-2414. PubMed ID: 29579334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.